Effects of anti-drug antibody on clinical efficacy and adverse reactions of immunotherapy for non-small cell lung cancer

Effects of anti-drug antibody on clinical efficacy and adverse reactions of immunotherapy for non-small cell lung cancer

Objective To explore the effects of anti-drug antibody (ADA) on clinical efficacy and adverse reactions in patients with non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs). Methods A total of 26 patients with stage Ⅲ/Ⅳ NSCLC undergoing pembrolizumab or nivolumab trea...

Full description

Bibliographic Details
Main Authors:	ZHAO Xianlan, LI Jixi, YANG Qiao, LI Shixun, YU Yongxin, LI Feng, LI Mengxia, SUN Jianguo
Format:	Article
Language:	zho
Published:	Editorial Office of Journal of Third Military Medical University 2021-09-01
Series:	Di-san junyi daxue xuebao
Subjects:	non-small cell lung cancer anti-drug antibody immune checkpoint inhibitors immune-related adverse events
Online Access:	http://aammt.tmmu.edu.cn/Upload/rhtml/202103060.htm

Similar Items

Rheumatological Adverse Events Following Immunotherapy for Cancer
by: Ioana Cretu, et al.
Published: (2022-01-01)

The Price of Success: Immune-Related Adverse Events from Immunotherapy in Lung Cancer
by: Courtney H. Coschi, et al.
Published: (2021-11-01)

Distinct patterns of auto-reactive antibodies associated with organ-specific immune-related adverse events
by: Mehmet Altan, et al.
Published: (2023-12-01)

Short review of immunotherapy toxicity
by: Ivana Canjko, et al.
Published: (2021-01-01)

Recent Advance in Biomarkers for Predicting Immune-related Adverse Events Caused by Immune Checkpoint Inhibitors
by: LI Ying, et al.
Published: (2021-04-01)

Clinical diagnosis and treatment recommendations for immune checkpoint inhibitor‐related hematological adverse events
by: Junling Zhuang, et al.
Published: (2020-03-01)

Clinical Diagnosis and Treatment Recommendations for Immune Checkpoint Inhibitor-related Hematological Adverse Events
by: Junling ZHUANG, et al.
Published: (2019-10-01)

Association between immune-related adverse events and immunotherapy efficacy in non-small-cell lung cancer: a meta-analysis
by: Li Lin, et al.
Published: (2023-05-01)

Preexisting autoantibodies as predictor of immune related adverse events (irAEs) for advanced solid tumors treated with immune checkpoint inhibitors (ICIs)
by: A Daban, et al.
Published: (2023-12-01)

Impact of immune‐related adverse events on survival outcomes in extensive‐stage small cell lung cancer patients treated with immune checkpoint inhibitors
by: Tadashi Nishimura, et al.
Published: (2024-04-01)

Rare immune-related adverse events in patients with melanoma: incidence, spectrum, and clinical presentations
by: Benjamin C. Park, et al.
Published: (2023-12-01)

Clinical diagnosis and treatment of immune checkpoint inhibitor‐associated adverse events in the digestive system
by: Yue Li, et al.
Published: (2020-04-01)

Clinical Diagnosis and Treatment of Immune-related Adverse Events in Digestive System Related to Immune Checkpoint Inhibitors
by: Yue LI, et al.
Published: (2019-10-01)

Rheumatic Immune-related Adverse Events and Treatment of Immune Checkpoint Inhibitors
by: ZHANG Xue, et al.
Published: (2020-11-01)

Toxicities of Immunotherapy for Small Cell Lung Cancer
by: Yang Fu, et al.
Published: (2021-05-01)

Resumption of anti‐programmed cell death 1 monotherapy for severe immune‐related adverse events experienced patient with renal cell carcinoma
by: Yoko Maegawa, et al.
Published: (2020-09-01)

Clarification of Hot Issues of Immune-Related Adverse Events
by: Yang FU, et al.
Published: (2024-09-01)

Advanced non-small cell lung cancer patient with a complete response and allergic immune-related adverse events by combined immunotherapy, including anti-CTLA-4 and anti-PD-1 antibodies: A case report
by: Chiho Nakashima, et al.
Published: (2024-06-01)

Management of immune checkpoint inhibitor‐related adverse events: A review of case reports
by: Xiaoyan Si, et al.
Published: (2020-03-01)

Recommendations and exploration of diagnosis and treatment of critical and refractory immune checkpoint inhibitor‐associated adverse events
by: Peng Song, et al.
Published: (2020-08-01)

Clinical Diagnosis and Treatment of Immune-related Adverse Events of Edocrine System Related to Immune Checkpoint Inhibitors
by: Lian DUAN, et al.
Published: (2019-10-01)

Real-world research of advanced NSCLC immunotherapy based on iRECIST criteria
by: CHEN Mingjing, et al.
Published: (2020-03-01)

Managing Select Immune-Related Adverse Events in Patients Treated with Immune Checkpoint Inhibitors
by: Parneet K. Cheema, et al.
Published: (2024-10-01)

Immunopathological basis of immune-related adverse events induced by immune checkpoint blockade therapy
by: Terufumi Kubo, et al.
Published: (2021-09-01)

Efficacy of immunotherapy in small cell lung cancer: A retrospective stude
by: Marina A. Lyadova, et al.
Published: (2024-08-01)

Immune‐related adverse events in non‐small cell lung cancer: Occurrence, mechanisms and therapeutic strategies
by: Xuwen Lin, et al.
Published: (2024-03-01)

Clinical Observation of Adverse Events of Immune Checkpoint Inhibitors in 20 Advanced Tumor Patients and Literature Reviews
by: WANG Xue, et al.
Published: (2020-06-01)

Management of Rheumatic Adverse Events Related to Immune Checkpoint Inhibitors
by: Jiaxin ZHOU, et al.
Published: (2019-10-01)

Management of immune checkpoint inhibitor‐related rheumatic adverse events
by: Jiaxin Zhou, et al.
Published: (2020-01-01)

Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
by: I. Puzanov, et al.
Published: (2017-11-01)

IMMUNE CHECKPOINT INHIBITORS AND RHEUMATIC ADVERSE EVENTS
by: Ioana Cretu, et al.
Published: (2018-12-01)

Clinical Recommendations for Perioperative Immunotherapy-induced Adverse Events in Patients with Non-small Cell Lung Cancer
by: Jun NI, et al.
Published: (2021-03-01)

Immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer: A review
by: Yuxuan Hao, et al.
Published: (2022-08-01)

Comparison of pneumonitis risk between immunotherapy alone and in combination with chemotherapy: an observational, retrospective pharmacovigilance study
by: Huixia Li, et al.
Published: (2023-04-01)

Ophthalmic immune-related adverse events associated with immune checkpoint inhibitors
by: Linyang Gan, et al.
Published: (2023-03-01)

Impact of Immunosenescence on Immune‐Related Adverse Events in Elderly Patients With Cancer
by: Jiayi Gao, et al.
Published: (2025-02-01)

Evaluating the potential of immunotherapy and chemoimmunotherapy in the treatment of elderly non-small cell lung cancer patients: A real-world study
by: Satoshi Endo, et al.
Published: (2023-01-01)

Analysis of characteristics and predictive factors of immune checkpoint inhibitor-related adverse events
by: Rilan Bai, et al.
Published: (2021-11-01)

Immune checkpoint inhibitor-related adverse cardiac events in patients with lung cancer: a systematic review and meta-analysis
by: Xiao-Tong Zhang, et al.
Published: (2022-11-01)

Immune-related adverse events of immune checkpoint inhibitors: a review
by: Qinan Yin, et al.
Published: (2023-05-01)